The results (Figure 1E) showed that SETD2 expression was upregulated in tumor vs. normal tissues in the cholangiocarcinoma (CHOL), hepatocellular carcinoma (LIHC) and stomach adenocarcinoma (STAD) and that SETD2 expression was downregulated in invasive breast carcinoma (BRCA), head-neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), thyroid carcinoma (THCA) and uterine corpus endometrial carcinoma (UCEC) datasets. Here, SETD2 is linked to uterine corpus endometrial carcinoma.